Viking Scientific is a dedicated team of scientists & innovators focused on improving the lives of patients and the caregivers that love them by working with industry leaders that can make a difference.
Our breakthrough technology is fast becoming a leading platform for the pharmaceutical industry.
Our platform provides a solution for issues related to compliance, toxicity, and cost while improving patient lives through sustained, consistent dosing.
Viking Scientific is a preclinical stage drug delivery company developing next-generation controlled release products that use drugs as building blocks to create biodegradable polymers with customizable properties. Our proprietary hydrogel prodrug platform can transform ordinary drugs into extended release formulations, providing days, weeks, or months of consistent drug release from a single treatment.
Our technology has been validated across a broad range of drug classes, providing sustained release solutions for small molecules, peptides, proteins, and antibodies.
Leadership
John Dempsey
Chief Executive Officer
John is a former VP at Johnson & Johnson SCG, with over 30 years of pharmaceutical industry and leadership experience. He was managing partner of WayPoint Consulting and President of Raintree Oncology (recently sold).
Gregory Fisher, MBA
Chief Financial Officer
Gregory has spent the past number of years based overseas in various leadership roles that have spanned Finance, Accounting and Operations at a publically-traded tech company. He is a registered CPA (inactive).
Paul Fisher, Ph.D.
Chief Science Officer
Paul is a biomedical engineer specializing in biodegradable polymers and drug delivery. Extensive experience working on FDA-approved in vitro diagnostics systems and clinical-stage DNA delivery systems.